Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL159387

CCCC[N+](CCCC)(CCCC)CCCC.O=C([O-])c1cccc(Cl)c1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
EPHX1 P07099 3/20 0.47
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
PARP1 P09874 1/20 0.44
EPHX2 P34913 4/20 0.42
SCN5A Q14524 3/20 0.42
SCN9A Q15858 3/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL8765761 0.95 ALDH1A1 (0.47) ALDH1A1HPGDEPHX1ERCC5FEN1
Tetrabuthylammonium SCHEMBL10603643 0.93 ALDH1A1 (0.46) ALDH1A1HPGDEPHX1ERCC5FEN1
Tributylmethylammonium SCHEMBL9790212 0.90 ALDH1A1 (0.50) ALDH1A1HPGDEPHX1ERCC5FEN1
Tetrabuthylammonium SCHEMBL107181 0.89 SMN1; SMN2 (0.47)
Cetrimonium SCHEMBL11203681 0.87 ALDH1A1 (0.48) ALDH1A1HPGDEPHX1ERCC5FEN1
Tetrabuthylammonium SCHEMBL512903 0.87 ALDH1A1 (0.52) ALDH1A1HPGDEPHX1ERCC5FEN1
Tetrabuthylammonium SCHEMBL107183 0.84 PLA2G4B (0.45)
Tetrabuthylammonium SCHEMBL11373850 0.84 PLA2G4B (0.45)
Isophthalic Acid SCHEMBL29465122 0.83 SMN1; SMN2 (0.45) ALDH1A1HPGD
Tetrabuthylammonium SCHEMBL3188178 0.81 CA1 (0.60) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534759-B1 MACROMER FORMING CATALYSTS JOHNSON & JOHNSON VISION CARE (US) 2009-09-09 EP claimed
US-20060004119-A1 Macromer forming catalysts JOHNSON & JOHNSON VISION CARE, INC. 2006-01-05 US claimed
CN-1675252-A Macromer forming catalysts JOHNSON & JOHNSON VISION CARE (US) 2005-09-28 CN claimed
EP-1534759-A1 MACROMER FORMING CATALYSTS Johnson & Johnson Vision Care, Inc. (US) 2005-06-01 EP claimed
US-20040002556-A1 Macromer forming catalysts JOHNSON & JOHNSON VISION CARE, INC. 2004-01-01 US claimed
WO-2004000888-A1 MACROMER FORMING CATALYSTS JOHNSON & JOHNSON VISION CARE, INC. (US) 2003-12-31 WO claimed
US-4736003-A HIGH MOLECULAR WEIGHT ACRYLIC POLYMERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-04-05 US claimed
US-4588795-A ADDITION POLYMERIZATION OF LIVING POLYMERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-05-13 US claimed
US-12636247-B2 Cosmetic SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-05-26 US disclosed
EP-4154970-B1 USE OF A DIBLOCK COPOLYMER AS EMULSIFIER SHINETSU CHEMICAL CO (JP) 2026-04-08 EP disclosed
US-12286543-B2 Image forming method Konica Minolta, Inc. (JP) 2025-04-29 US disclosed
CN-119781244-A Photosensitive composition for color filter, image display device, and solid-state imaging element 爱天思株式会社 2025-04-08 CN disclosed
CN-114341215-B Curable composition 株式会社日本触媒 2024-12-27 CN disclosed
US-12116492-B2 Non-pigmented dispersant composition BYK-CHEMIE GMBH (DE) 2024-10-15 US disclosed
EP-0248596-A2 Durable epoxy (meth) acrylic polymer with oxirane-containing terminal groups and preparation E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-09 EP disclosed
WO-1987007265-A1 ACYLATION AND SULFONATION OF SILYLKETENE ACETALS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-12-03 WO disclosed
EP-0244953-A1 Enhanced livingness of polymerization using silylated oxyanions E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-11-11 EP disclosed
EP-0243120-A2 Tough flexible polymer blends E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-10-28 EP disclosed
EP-0218436-A2 Acrylic pigment dispersant made by group transfer polymerization E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-04-15 EP disclosed
US-4656226-A BLOCK POLYMERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636247-B2 Cosmetic MSR1, TLR3, LOXL1 ALDH1A1 459/4885HPGD 1753/4885EPHX1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.